Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC) that has been assessed as not suitable for surgery or a liver transplant, with one or more tumours where no single tumour is larger than 15 cm and the total size of all tumours combined is less than 20 cm.
• People whose liver cancer diagnosis has been confirmed either by a tissue or cell sample test, or by a specific pattern seen on a CT or MRI scan.
• People aged 18 or older at the time of signing the consent form.
• People whose general health and ability to carry out daily activities meets a certain standard (rated 0 or 1 on a scale used by doctors, meaning fully active or able to carry out light work) (confirm with trial site).
• People whose liver cancer is classified as intermediate (Stage B) or advanced (Stage C) using a liver cancer staging system called BCLC (confirm with trial site).
• People whose liver function has been assessed as reasonably well preserved within the 28 days before joining the study, using a scoring system called Child-Pugh (scores 5–6) (confirm with trial site).
• People who have had their hepatitis B virus (HBV) status tested and documented before joining the study.
• People who have had their hepatitis C virus (HCV) status tested and documented before joining the study.
• People who are willing and able to understand and sign a written consent form.
• People whose blood, liver, and kidney test results fall within acceptable ranges within the 4 weeks before joining — including adequate red blood cell levels, white blood cell levels, platelet counts, liver function markers, kidney function markers, and blood clotting measures (confirm with trial site for specific values).

Who may not be able to join:

• People who have had another type of cancer in the past, unless they have been free of that cancer for at least 2 years.
• People who have previously had radiation treatment to the liver area in a way that would overlap with the radiation planned in this trial.
• People who have ever had a type of internal radiation treatment delivered through the blood vessels to the liver (called selective internal radiotherapy or hepatic arterial yttrium therapy).
• People who have active hepatitis B or hepatitis C that has not been treated.
• People who have a moderate to severe or difficult-to-manage build-up of fluid in the abdomen (ascites).
• People who have cancer that has spread to distant parts of the body in a way that cannot be treated with the radiation therapy used in this trial.
• People who have untreated or incompletely treated enlarged veins in the oesophagus or stomach (varices).
• People with serious ongoing health conditions, including: unstable chest pain or heart failure requiring hospitalisation in the past 6 months; a heart attack in the past 6 months; a severe bacterial or fungal infection requiring IV antibiotics in the past 28 days; any bleeding episode in the past 6 months; clot-dissolving (thrombolytic) treatment in the past 28 days; a known bleeding or clotting disorder; or an uncontrolled psychiatric condition.
• People who are pregnant, or women who could become pregnant and men who are sexually active but are unable or unwilling to use an appropriate form of contraception.
• People who have previously had a solid organ transplant (such as a kidney, heart, or liver transplant).
• People who have or have had an autoimmune disease — a condition where the immune system attacks the body — such as autoimmune hepatitis, lupus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, or similar conditions.
• People who have or have had blood clotting or bleeding disorders, coughing up blood, a stroke, significant heart disease, or a perforation (hole) in the stomach or intestines.
• People whose cancer cannot be fully treated with the radiation therapy used in this trial — for example, if cancer has spread outside the liver in a way that cannot be covered, or if the liver tumours are too large to treat safely.
• People who have a known HIV infection.

Important: Always verify eligibility with the trial site directly before applying.